Shares of HUTCHMED (China) Limited (LON:HCM – Get Free Report) dropped 3.7% during mid-day trading on Wednesday . The stock traded as low as GBX 258 ($3.26) and last traded at GBX 260 ($3.28). Approximately 44,821 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 88,241 shares. The stock had previously closed at GBX 270 ($3.41).
HUTCHMED Trading Down 1.6 %
The firm has a 50 day moving average of GBX 287.36 and a 200-day moving average of GBX 283.59. The company has a quick ratio of 2.97, a current ratio of 2.81 and a debt-to-equity ratio of 11.78. The firm has a market capitalization of £2.11 billion, a P/E ratio of -6,425.00 and a beta of 0.76.
About HUTCHMED
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Featured Articles
- Five stocks we like better than HUTCHMED
- Consumer Staples Stocks, Explained
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Overbought Stocks Explained: Should You Trade Them?
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is the Euro STOXX 50 Index?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.